✨ Onyx Summary Belite Bio announced it will host a webcast on March 2, 2026 at 4:30 p.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a business update. A live webcast and a replay (available for about 90 days) will be accessible via the company’
✨ Onyx Summary Affinia Therapeutics said the European Medicines Agency has granted Orphan Drug designation to AFTX-201, its investigational AAV gene therapy for BAG3-associated dilated cardiomyopathy, following the FDA’s acceptance of its IND. The designation adds regulatory incentives and market-exclusivity potential in the EU as Affinia advances a one-time intravenous
✨ Onyx Summary Verily launched self-serve access to its Pre precision health platform, adding a free Standard tier that lets individual researchers use Exchange and the Workbench secure analysis environment to discover and analyze select biomedical datasets under a data use agreement. The company also outlined additional data sources coming to
✨ Onyx Summary Cellares and the University of Wisconsin School of Medicine and Public Health expanded their partnership to move UW’s CRISPR-edited GD2 CAR-T program for solid tumors into clinical manufacturing and support an FDA IND submission, with Cellares providing automated manufacturing (Cell Shuttle) and automated QC (Cell Q) plus
✨ Onyx Summary Perspective Therapeutics said it will report full-year 2025 financial results and provide a business update after market close on Monday, March 16, 2025, with the release posted to the company’s newsroom. The update will frame progress across its 212Pb-based theranostic platform and Phase 1/2a programs in
✨ Onyx Summary Verily says its Verily Pre precision health AI platform has achieved “Awardable” status on the Department of War CDAO’s Tradewinds Solutions Marketplace, positioning it as a readily awardable option for DoW agencies. The designation is intended to streamline federal procurement and expands Verily’s path from existing
✨ Onyx Summary Recursion’s board compensation committee approved inducement RSU awards covering 820,431 shares to 17 new employees under its 2024 Inducement Equity Incentive Plan, with quarterly vesting beginning after a one-year anniversary milestone and continuing until fully vested, contingent on continued employment. The grants, issued under Nasdaq Rule
✨ Onyx Summary Geron said it will report fourth-quarter and full-year 2025 financial results and business highlights before the market opens on February 25, 2026, followed by an 8:00 a.m. ET conference call and webcast. The update will give investors the latest view on commercialization of RYTELO (imetelstat) in
✨ Onyx Summary SpyGlass Pharma closed its IPO of 10,781,250 common shares at $16.00 per share, including the full exercise of the underwriters’ option, raising $172.5 million in gross proceeds and beginning Nasdaq Global Select Market trading under “SGP” on February 6, 2026. The financing provides public-market
✨ Onyx Summary Ocugen appointed Rita Johnson-Greene as chief financial officer, citing her leadership experience across regenerative medicine and gene therapy organizations including ARM, bluebird bio (Genetix Biotherapeutics), Spark Therapeutics, and AstraZeneca. The hire comes as Ocugen prepares to submit the first of three planned biologics license applications this year, aligning
✨ Onyx Summary Lexicon closed a public offering of 32.0 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares plus 367,145 shares of Series B convertible preferred stock priced at $65 per share, with both transactions closing on February
✨ Onyx Summary Phathom Pharmaceuticals announced that its management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on February 12, alongside one-on-one investor meetings during the conference. The appearance underscores the company’s ongoing investor engagement as it advances and commercializes its gastrointestinal disease
✨ Onyx Summary SpyGlass Pharma priced its initial public offering of 9.4 million shares at $16.00 per share, raising approximately $150 million in gross proceeds ahead of its Nasdaq Global Select Market debut under the ticker “SGP.” The IPO provides capital to advance the company’s late-stage, long-acting drug
✨ Onyx Summary Seer, Inc. announced it will report fourth-quarter and full-year 2025 financial results on February 26, 2026, followed by a webcasted conference call with management later that day. REDWOOD CITY, Calif., Feb. 05, 2026 – Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today
✨ Onyx Summary enGene Holdings announced that CEO Ron Cooper will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11. The presentation highlights continued investor engagement as the company advances its non-viral genetic medicine platform and lead program for non-muscle invasive bladder cancer. BOSTON
✨ Onyx Summary Affinia Therapeutics said the U.S. Food and Drug Administration has accepted its IND application for AFTX-201, clearing the company to initiate a Phase 1/2 clinical trial in adults with genetically confirmed BAG3-associated dilated cardiomyopathy. The decision advances a first-in-class gene therapy program targeting a severe inherited
